Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan.
Journal
Journal of the Formosan Medical Association = Taiwan yi zhi
ISSN
0929-6646
Date Issued
2025-04-11
Author(s)
Li, Jian-Ri
Chiu, Kun-Yuan
Su, Po-Jung
Su, Yu-Li
Chung, Hsiao-Jen
Li, Ching-Chia
Huang, Chi-Ping
Guo, Jhe-Cyuan
Chen, Chuan-Shu
Chang, Irene
Perrot, Valérie
Chang, Yen-Hwa
Abstract
There is a lack of real-world evidence from Taiwan on the use of cabozantinib for advanced renal cell carcinoma (aRCC). We evaluated cabozantinib treatment for aRCC after previous antiangiogenic therapy in real-world Taiwanese clinical practice.
Medical records from seven Taiwanese hospitals were retrospectively analyzed. Eligible patients were adults with aRCC who initiated cabozantinib between October 2018 and August 2021 after ≥1 antiangiogenic therapy. Patient characteristics and treatment patterns were described. Outcomes included objective response rate (ORR [complete or partial]; primary endpoint) assessed by RECIST v1.1 or local investigator assessment, progression-free survival (PFS), and tolerability.
Fifty-one patients were included: 39.2 % received cabozantinib second-line, 33.3 % third-line, and 27.5 % fourth- or later-line. Mean patient age was 61.2 years; most were male (80 %), had clear-cell (80 %), metastatic (92 %) disease, and had previous nephrectomy (78 %). Sunitinib and pazopanib were the most common previous (any line) treatments (63 % and 53 % of patients, respectively). Dose reductions occurred in 47 % of patients and were more common in patients (57 %) who initiated cabozantinib at 60 mg/day than in those (33 %) who initiated at 40 mg/day (72 % vs 12 %, respectively); discontinuation rates were similar for these groups (48 % vs 47 %, respectively). Overall, ORR was 39.2 % (95 % CI: 25.8, 53.9) and median PFS was 12.4 months (95 % CI: 8.2, 16.3). Rates of serious treatment-emergent adverse events related to cabozantinib were low (7.8 %).
This Taiwanese study found the real-world effectiveness and tolerability of cabozantinib after previous antiangiogenic therapy to be consistent with the results of the METEOR trial.
Subjects
Advanced renal cell carcinoma
Cabozantinib
Real-world
Taiwan
Type
journal article